ArticleAnnals of clinical and translational neurology2026
Risk of Non-Arteritic Anterior Ischemic Optic Neuropathy in Idiopathic Intracranial Hypertension Patients Treated with GLP-1 Receptor Agonists.
Article in Annals of clinical and translational neurology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introductionGlucagon-like peptide-1 receptor agonists (GLP-1 RAs) have demonstrated significant weight-reducing effects and may offer benefits in idiopathic intracranial hypertension (IIH); however, recent concerns about the risk of non-arteritic anterior ischemic optic neuropathy (NAION) have emerged. Hence, this study was designed to examine the relationship between GLP-1 RA use and optic outcomes in IIH patients.
methodsThis study used the TriNetX Global Collaborative Network to perform a retrospective propensity score-matched cohort study. It involved GLP-1 RA exposure status to classify adult patients with IIH. Further, it applied propensity score matching (PSM) on demographics, comorbidities, and medications. In this study, the primary outcome was incident NAION; the secondary outcome was optic atrophy. Cox proportional hazards regression, time-stratified analyses, and multiple testing corrections were performed.
resultsFrom 144,678 IIH patients, 15,567 matched pairs were analyzed. GLP-1 RA use demonstrated significantly decreased NAION risk (hazard ratio [HR] 0.47, 95% confidence interval [CI] 0.24-0.93, p = 0.027) and optic atrophy risk (HR 0.78, 95% CI 0.64-0.94, p = 0.009). Time-stratified analyses have demonstrated protective associations across all evaluated time windows. The optic atrophy finding remained significant after Bonferroni correction, while NAION remained significant after false discovery rate correction. Subgroup analysis revealed stronger protective associations in non-diabetic patients (risk ratio 0.53, 95% CI 0.41-0.68) compared to diabetic patients (risk ratio 0.76, 95% CI 0.58-0.99).
conclusionsGLP-1 RA utilization among IIH patients was associated with a reduced risk of NAION and optic atrophy. These findings align with the proposed pathway linking GLP-1 RA-induced weight reduction to lower intracranial pressure and papilledema reduction in IIH patients; residual confounding cannot be ruled out, and prospective studies are needed to confirm these associations.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.